DISCORDANT VIRUS NEUTRALIZATION AND ANTI-HIV ADCC ACTIVITY IN HIV-SEROPOSITIVE PATIENT SERA NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


DISCORDANT VIRUS NEUTRALIZATION AND ANTI-HIV ADCC ACTIVITY IN HIV-SEROPOSITIVE PATIENT SERA

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 323-6, 1988.. Unique Identifier : AIDSLINE ICDB/89649776
Lyerly HK; Pratz JE; Tyler DS; Matthews TJ; Langlois AJ; Bolognesi DP; Weinhold KJ; Surgical Virology Lab., Dept. of Surgery, Duke Univ. Medical; Center, Durham, NC 27710

Abstract: Studies were undertaken to demonstrate HIV-neutralizing capacity in patient (pt) sera and to compare the ability of the serum antibodies to (1) neutralize free virus; (2) inhibit cell fusion between HIV-infected cells and CD4+ cells; and (3) direct antibody-dependent cellular cytotoxicity (ADCC). These functions were assessed using sera from 30 seropositive pts. Although there was a good correlation between virus neutralization and the ability to block infected cell-to-cell fusion, discordance in virus neutralization and ADCC activity was found in pt sera. Furthermore, immunoaffinity-purified anti-gp120 antibodies had only type-specific neutralizing activity, but they retained the ability to direct ADCC against divergent viral strains. The present results suggest that antibodies to different epitopes of gp120 may be involved in virus neutralization and ADCC. Candidate vaccines must take into account the ability of immunogens to elicit both virus neutralization and anti-HIV ADCC activity. (5 Refs)
Keywords: *Antibody-Dependent Cell Cytotoxicity Cell Line Human HIV/*IMMUNOLOGY HIV Antibodies/*BIOSYNTHESIS HIV Seropositivity/*IMMUNOLOGY *Neutralization Tests Retroviridae Proteins/IMMUNOLOGY MEETING PAPER

KWDantibody-dependentcellcytotoxicitycelllinehumanhiv/KWDimmunologyhivantibodies/KWDbiosynthesishivseropositivity/KWDimmunologyKWDneutralizationtestsretroviridaeproteins/immunologymeetingpaper
890330
M8930536

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .